Antiresorptive agents are widely used to treat osteoporosis. Both reduction in bone turnover and increase in BMD may be necessary to decrease the fracture risk. Th e aim of the study was to evaluate the eff ects of aledronate on bone turnover markers and bone mineral density in postmenopausal women with osteoporosis. Th e study involved a group of  postmenopausal women with osteoporosis treated with alendronate ( mg) weekly at the Institute of Nuclear Medicine Clinical Center University of Sarajevo during a -months period. Bone mineral density (BMD) at lumbar spine and proximal femur and bone turnover markers (serum β-CrossLaps, urinary N-telopeptides of type I collagen (NTx), total serum alkaline phosphatase (AP) and serum osteocalcin) were measured at baseline and after  months of the treatment with aledronate. BMD values signifi cantly increased both at lumbar spine by . 
Introduction
Osteoporosis is defined as a skeletal disorder characterized by compromised bone strength, predisposing a person to an increased risk of fracture [] . Properties related to bone strength include rate of bone turnover, BMD, geometry, microarchitecture, and mean degree of mineralization [] . During the postmenopausal osteoporosis, bone resorption exceeds formation, resulting in decreased bone mass and deterioration of the microarchitecture, with consequent decreased bone strength and increased susceptibility to fracture [] . In particular, hip fractures are an important cause of mortality and morbidity among postmenopausal women. The proximal femur of the hip is primarily composed of cortical bone. In cortical bone, high bone turnover, as observed after the menopause, is associated with decreased BMD, increased cortical porosity due to increased bone remodelling in the Haversian canal, decreased cortical thickness due to increased endocortical bone remodelling, and decreased mean degree of mineralization [, ] . Treatment with potent anti-resorptive drugs is a strategy for preventing hip fractures in postmenopausal women. Several therapeutic agents are currently available to treat or prevent postmenopausal osteoporosis [, ] . Among commercially available drugs, however, only alendronate, risedronate, intravenous zoledronate, strontium ranelate, and hormone replacement therapy (HRT) have shown anti-fracture effi cacy against hip fractures in post-menopausal women [] . Alendronate and risedronate, which are the second-and third-generation bisphosphonates, respectively, have been used as fi rst-line drugs in the treatment of osteoporosis for many years. For example, Black et al. [] have found that three years of treatment with alendronate increases lumbar spine bone mineral density (BMD) by about  and reduces vertebral fracture rate by about  [] . Interestingly, alendronate treatment results in a  greater BMD increment in the lumbar spine than the hip, but reduces fracture risk at both sites by roughly the same degree [] . Th is suggests that factors other than BMD play an important role in dictating the eff ects of bisphosphonates on preventing bone fractures. These factors may include the site specific biomechanical milieu, the propensity to fall or alterations in the bone tissue matrix properties. It has also been proposed that the pretreatment rate of bone turnover contributes to the ability of bone to resist fracture [, ] . Clinical studies have found that after adjusting for BMD, the biochemical markers of bone turnover can still predict fracture risk [, ] . Because elevated bone turnover markers and low bone mineral density (BMD) are independent predictors of hip fracture risk, and the risk is multiplied when both are present, bone turnover and BMD are important factors in decreasing the risk of hip fractures [] . Both reduction in bone turnover and increase in hip BMD may be necessary to decrease the fracture risk of the hip, which is primarily composed of cortical bone and may require greater proportionate changes than trabecular bone [, ] . In fact, drugs with a smaller eff ect on bone turnover reduce the risk of only vertebral fractures, whereas those with a greater eff ect reduce the risk of both vertebral and nonvertebral fractures including hip fractures [] . Th e aim of the study was to evaluate the eff ects of aledronate treatment during -months period on bone turnover including bone formation and bone resorption markers and bone mineral density in postmenopausal women with osteoporosis.
Materials and Methods

Patients
Th e study involved a group of  postmenopausal women (mean age was .±. years, mean menopause duration .±. years) diagnosed with osteoporosis and treated at the Institute of Nuclear Medicine Clinical Centre University of Sarajevo. Osteoporosis was diagnosed based on the bone mineral density (BMD) T-score values ≤ -. at the lumbar spine and/or proximal femur measured with dual-energy xray absorptiometry (DEXA). None of the subjects suff ered from any metabolic bone diseases, had a history of hormone (estrogen) replacement therapy, or had ever taken medication known to aff ect bone metabolism prior to the present study. Informed consent was obtained from each participant prior to participation in the study. Pre-existing vertebral fractures were documented in . of patients. All of patients included in the study received alendronate  mg weekly (Fosamax T, Merck) and were instructed to take the medication consistent with the instructions in the product insert. Th ey received also  mg of calcium citrate daily and  IU of Vitamin D.
Measurement of Bone turnover markers
Serum C-terminal telopeptides of type I collagen fragment (β-CrossLaps) and urinary N-telopeptide of type I collagen (NTx) as markers of bone resorption and osteocalcin and serum alkaline phosphate (ALP), as a markers of bone formation, were measured in patients at baseline and at  months. Blood and urine specimens were collected on the same day and stored frozen (- o C) until measurement. Serum osteocalcin and β-CrossLaps levels were measured using electrochemiluminescent immunoassay (ECLIA) on Rosche Elecsys system at Institute of Nuclear medicine. Referral values using this method for osteocalcin are - ng/ mL and for β-Crosslaps <. ng/mL. Urinary NTx level was determined by chemiluminescent method on Vitros EciQ Immunidiagnostic system (Orthro-Clinical Diagnostic) at the Institute for Clinical chemistry and biochemisty at Clinical Center University of Sarajevo. Urinary sample was collected in an early morning, second voided urine sample, stored at -°C for later analysis. Referral values for urinary NTx using this method are - nMBCE/mM Cr. Serum calcium and AP were measured using standard methods.
Measurement of BMD
BMD was measured at the time of study entry (baseline) and after  months. BMD of the lumbar spine (L-L) in the posteroanterior projection and femoral neck (left side), expressed in g/cm and converted to T-score values, was measured with dual-energy x-ray absorptiometry (DEXA) on QDR ; Hologic system. All DEXA measurements were done at the Institute of Radiology at Clinical Centre University of Sarajevo.
Statistical analysis
All values were expressed as mean±SEM. Th e paired t test was used to compare differences in bone turnover markers (ALP, osteocalcin, β-Crosslaps and NTx) and BMD between baseline and  months of treatment. P value less than . was considered statistically significant. All statistical analysis were performed with the SPSS  software (version ., SPSS Inc, Chicago, Illinois, USA). Table  shows longitudinal changes in serum calcium and bone turnover markers levels. A signifi cant reduction in bone resorption markers during the study period was observed. Serum β-CrossLaps decreased by . (.±. vs. .±. ng/mL; p<.) and urinary NTX level by . after the  months of treatment (.±. vs..±. nMBCE/mM Cr; p=.). Also, signifi cant reduction by . in serum alkaline phosphatase was observed which decreased from baseline values, .±. IU/L, to .±. IU/L at the end of the study period (p<.). Serum osteocalcin level also signifi cantly decreased from .±. to .±. ng/ mL (p=.), while there were no changes in serum calcium level during the -months period (Table , Figure  ).
Results
ELMA KUČUKALIĆSELIMOVIĆ ET AL.: EVALUATION OF BONE REMODELLING PARAMETERS AFTER ONE YEAR TREATMENT WITH ALENDRONATE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
BMD T-score values significantly increased both at lumbar spine and proximal femur by . and ., respectively ( Figure  ) during the -months treatment period. T-score values at lumbar spine significantly increased from -.±. to -.±. and at proximal femur from -.±. to -.±. (p<.)( Table ) .
Discussion
The results of our study show that the treatment of postmenopausal osteoporosis with aledronate during the  months period is effective in increasing the BMD both at lumbar spine and proximal femur. In our study, BMD increased at lumbar spine by . and proximal femur by .. Our results are in concordance with the results from other studies which have observed increases in bone mineral density by . percent at the lumbar spine, . percent at the trochanter, . percent at the femoral neck and . percent at the total proximal femur as compared with base-line values [, ] . Meta-analysis conducted by Papapoulos et al. [] [] who demonstrated that suppression of bone turnover and an increase in vertebral BMD contribute equally to the propensity of bone to resist a vertebral fracture. Riggs et al. [] proposed that the effi cacy of the suppression of bone turnover rate in reducing the incidence of bone fractures could be explained by considering the pre-treatment turnover rate. Th e high turnover rate in the vertebra may exacerbate the eff ects of bone loss by accelerating the loss of trabecular connectivity and thickness [, , ] . Normalization of the bone turnover rate in the vertebra, therefore, reduces the eff ects of high turnover rate on the microarchitectural deterioration and improve bone's biomechanical properties even more than expected based on BMD alone [, , ] . Furthermore, aledronate treatment during  months in our study was eff ective in reducing the level of bone turnover markers. Serum β-CrossLaps decreased by . and urinary NTX level by .. Our results are in line with the results from other studies [, , ] . Moreover, treatment with alendronate will suppress but will not abolish bone turnover. Bone turnover will be reduced to a non-zero limit and it will reach this limit regardless of the pre-treatment remodeling rate or the treatment dose. In agreement with these observations, clinical trials have demonstrated that in postmenopausal women treated up to  years with  mg or  mg of alendronate, bone turnover reaches a non-zero steady state after about  months of treatment [] . More importantly, both doses suppress bone turnover to a similar limit [] . Alendronate inhibits osteoclastic bone resorption, by reducing bone turnover, increasing hip BMD, decreasing cortical porosity, and produces more uniform mineralization (ie, increases the mean degree of mineralization of bone (MDMB) in cortical bone, possibly contributing to a reduction in the risk of hip fractures [, ] . In alendronate-treated postmenopausal women, the distribution of the degree of mineralization in cortical bone shows a clear shift toward the highest mineralization values and a decrease in the number of bone structure units having low values of mineralization [] . Th e MDMB augmentation probably accounts for most of the increase in BMD seen with alendronate. According to the hypothesis proposed by Boivin et al. [] , the reduction in the activation frequency caused by the anti-resorptive eff ect of alendronate is followed by a prolonged secondary mineralization that increases the percentage of bone structure units having reached a maximum degree of secondary mineralization and, though this mechanism, augmentation of the MDMB. Evidence derived from the literature, stratified and based on strict EBM guidelines, suggests the efficacy of alendronate against hip fractures in postmenopausal women with osteoporosis with an overall risk reduction rate of . According to the analyses of the Fracture Intervention Trial, each  standard deviation reduction in a -year change in bone-specific-alcalinee phospathase BSAP is associated with  fewer hip fractures in alendronate-treated postmenopausal women, and those with at least a  reduction in BSAP have a  lower risk of hip fractures relative to those with less than  [] . Alendronate is eff ective in reducing the risk of hip fractures across a spectrum of ages. Th e mechanism for this anti-fracture effi cacy has been clarifi ed; alendronate suppresses bone turnover and subsequently increases hip BMD, decreases cortical porosity, improves parameters of hip structure geometry (cortical thickness, crosssectional area, section modulus, and buckling ratio), and produces more uniform mineralization (increases the MDMB) in cortical bone. A once-weekly alendronate regimen provides better adherence (compliance and persistence) of the patients to the treatment than the once-daily dosing regimen, leading to greater efficacy against hip fractures. Thus, the effi cacy of alendronate against hip fractures has been confirmed in postmenopausal women with osteoporosis, especially with once-weekly dosing regimen [, , , ] .
Conclusion
Alendronate treatment during  months period, administered once-weekly is effective in increasing BMD both at lumbar spine and femoral neck and reducing bone turnover. Therefore, the treatment with aledronate can be recommended in postmenopausal women with osteoporosis which decreases the eff ects of high turnover rate on the microarchitectural deterioration and improves bone's biomechanical properties.
